Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Melanoma 116Carcinoma, Non-Small-Cell Lung 101Carcinoma, Renal Cell 67Colorectal Neoplasms 46Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 38Carcinoma, Hepatocellular 38Neoplasms 35Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 16Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

Nivolumab 3capivasertib 2Gemcitabine 2Cisplatin 2tivozanib 1regorafenib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1encorafenib 1durvalumab 1copanlisib 1cemiplimab 1axicabtagene ciloleucel 1avasopasem manganese 1Valproic Acid 1Thioctic Acid 1Taxes 1Receptors, Interleukin-6 1Radiosurgery 1RNA-Seq 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1Lenalidomide 1Interleukin 1 Receptor Antagonist Protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Disease Progression × Nivolumab × 1 year × Clear all
NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

NCT03259867 2026-04-16

TATE-PD1

Teclison Ltd.

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡